Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months
Clinical trial NCT04826198 · TERMINATED
Trial details
- NCT number
- NCT04826198
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-05
- Primary completion
- 2024-04-04
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.